专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011041319A8 SPECIFIC BINDING PROTEINS AND USES THEREOF 审中-公开
标题翻译：特异性结合蛋白及其用途
公开(公告)号：WO2011041319A8
公开(公告)日：2011-10-06
申请号：PCT/US2010050559
申请日：2010-09-28
申请人： LUDWIG INST FOR CANCER RES LTD , OLD LLOYD J , JOHNS TERRANCE GRANT , PANOUSIS CON , SCOTT ANDREW MARK , RENNER CHRISTOPH , JUNGBLUTH ACHIM , STOCKERT ELIZABETH , COLLINS PETER , CAVENEE WEBSTER K , HUANG HUEI-JEN SU , BURGESS ANTONY WILKS , NICE EDOUARD COLLINS , MURRAY ANNE , MARK GEORGE , RITTER GERD
发明人： OLD LLOYD J , JOHNS TERRANCE GRANT , PANOUSIS CON , SCOTT ANDREW MARK , RENNER CHRISTOPH , JUNGBLUTH ACHIM , STOCKERT ELIZABETH , COLLINS PETER , CAVENEE WEBSTER K , HUANG HUEI-JEN SU , BURGESS ANTONY WILKS , NICE EDOUARD COLLINS , MURRAY ANNE , MARK GEORGE , RITTER GERD
IPC分类号： A61K51/10 , A61P35/00 , C07K16/28 , C07K16/30
CPC分类号： C07K16/2863 , A61K39/39558 , A61K51/103 , A61K51/1045 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/30 , C07K16/4266 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译：本发明涉及与扩增的表皮生长因子受体（EGFR）结合并与EGFR的de2-7 EGFR截短结合的特异性结合成员，特别是抗体及其片段。具体而言，特异性结合成员识别的表位，特别是抗体及其片段，在异常翻译后修饰时增强或明显。这些特异性结合成员可用于癌症的诊断和治疗。本发明的结合成员还可以与化学治疗剂或抗癌剂和/或其他抗体或其片段组合用于治疗。

3. 发明专利

AU2021200582A1 Anti-GITR antibodies and methods of use thereof 未知
公开(公告)号：AU2021200582A1
公开(公告)日：2021-03-04
申请号：AU2021200582
申请日：2021-01-29
申请人： AGENUS INC , LUDWIG INST FOR CANCER RES LTD , MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： LEGER OLIVIER , SIEBERT VOLKER , VAN DIJK MARC , SCHAER DAVID , TSUJI TAKEMASA , RITTER GERD , GONZALEZ ANA M , WILSON NICOLAS S , ZAPPASODI ROBERTA , MERGHOUB TAHA , WOLCHOK JEDD DAVID , UNDERWOOD DENNIS J
IPC分类号： C07K16/28 , A61K39/395
摘要： Abstract The present disclosure provides antibodies that specifically bind to human glucocorticoid induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

4. 发明专利

SG10201912984WA ANTIBODIES AND METHODS OF USE THEREOF 未知
公开(公告)号：SG10201912984WA
公开(公告)日：2020-03-30
申请号：SG10201912984W
申请日：2016-12-02
申请人： AGENUS INC , MEMORIAL SLOAN KETTERING CANCER CENTER , LUDWIG INST FOR CANCER RES LTD
发明人： WILSON NICHOLAS S , WAIGHT JEREMY D , RITTER GERD , SCHAER DAVID , HIRSCHHORN-CYMERMAN DANIEL , MERGHOUB TAHA , BREOUS-NYSTROM EKATERINA V , SEIBERT VOLKER , TSUJI TAKEMASA , LEGER OLIVIER , UNDERWOOD DENNIS J , VAN DIJK MARC
摘要： The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.

5. 发明专利

SG10201912986PA ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOF 未知
公开(公告)号：SG10201912986PA
公开(公告)日：2020-02-27
申请号：SG10201912986P
申请日：2015-05-28
申请人： AGENUS INC , MEMORIAL SLOAN KETTERING CANCER CENTER , LUDWIG INST FOR CANCER RES LTD
发明人： LEGER OLIVIER , SIEBERT VOLKER , VAN DIJK MARC , SCHAER DAVID , TSUJI TAKEMASA , RITTER GERD , GONZALEZ ANA M , WILSON NICOLAS S , ZAPPASODI ROBERTA , MERGHOUB TAHA , WOLCHOK JEDD DAVID , UNDERWOOD DENNIS J
摘要： The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity,.., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity.., enhances, activates or induces GITR activity.

6. 发明专利

SG10201912560YA ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF 未知
公开(公告)号：SG10201912560YA
公开(公告)日：2020-02-27
申请号：SG10201912560Y
申请日：2017-12-07
申请人： AGENUS INC , LUDWIG INST FOR CANCER RES LTD , MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： VAN DIJK MARC , MUNDT CORNELIA , RITTER GERD , SCHAER DAVID , WOLCHOK JEDD , MERGHOUB TAHA , WILSON NICHOLAS , SAVITSKY DAVID , FINDEIS MARK , UNDERWOOD DENNIS , CUILLEROT JEAN-MARIE , PROSCURSHIM IGOR , SHEBANOVA OLGA
摘要： The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

8. 发明专利

AR110348A1 ANTICUERPOS Y MÉTODOS DE SU UTILIZACIÓN 未知
公开(公告)号：AR110348A1
公开(公告)日：2019-03-20
申请号：ARP170103466
申请日：2017-12-12
申请人： AGENUS INC , LUDWIG INST FOR CANCER RES LTD , MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： HOLMGAARD RIKKE B , ZAPPASODI ROBERTA , FINDEIS MARK A , SAVITSKY DAVID A , WILSON NICHOLAS S , MERGHOUB TAHA , WOLCHOK JEDD D , SCHAER DAVID , RITTER GERD , MUNDT CORNELIA A , VAN DIJK MARC
IPC分类号： A61K39/395 , A61P35/00 , A61P37/00 , A61P37/04 , C07K16/28
摘要： Son suministrados anticuerpos que se ligan específicamente a CTLA-4 y/o PD-1 y antagonizan la función de CTLA-4 y/o PD-1. También se suministran composiciones farmacéuticas y kits que comprenden dichos anticuerpos, ácidos nucleicos que codifican dichos anticuerpos, vectores de expresión y células hospedadoras para la producción de dichos anticuerpos y métodos de tratamiento de pacientes utilizando dichos anticuerpos, aisladamente o en combinación. Reivindicación 1: Método de incremento o inducción de reacción inmunológica en pacientes, en que el método comprende la administración al paciente de una cantidad eficaz de una combinación terapéutica que comprende un primer anticuerpo aislado que se liga específicamente a CTLA-4 humano y un segundo anticuerpo aislado que se liga específicamente a PD-1 humano, en que el primer anticuerpo aislado comprende una región variable de cadena pesada que comprende las regiones de determinación de la complementariedad CDRH1, CDRH2 y CDRH3 y una región variable de cadena ligera que comprende las regiones de determinación de la complementariedad CDRL1, CDRL2 y CDRL3, en que: a) CDRH1 comprende la secuencia de aminoácidos de SYX¹MX² (SEQ ID Nº 39), en que: X¹ es S o A; y X² es N o S; b) CDRH2 comprende la secuencia de aminoácidos de SISSSSSYIYYADSVKG (SEQ ID Nº 22); c) CDRH3 comprende la secuencia de aminoácidos de VGLMGPFXI (SEQ ID Nº 115), en que X es D o N; d) CDRL1 comprende la secuencia de aminoácidos de RASQSVX¹X²YLX³ (SEQ ID Nº 43), en que: X¹ es S o G; X² es R, S, o T; y X³ es G o A; e) CDRL2 comprende la secuencia de aminoácidos de X¹X²SX³RAT (SEQ ID Nº 44), en que: X¹ es G o A; X² es A o T; y X³ es T, S, R o N; y f) CDRL3 comprende la secuencia de aminoácidos de QQYGX¹SPX²T (SEQ ID Nº 45), en que: X¹ es S o T; y X² es W o F; en que el segundo anticuerpo aislado comprende una región variable de cadena pesada que comprende las regiones de determinación de la complementariedad CDRH1, CDRH2 y CDRH3 y una región variable de cadena ligera que comprende las regiones de determinación de la complementariedad CDRL1, CDRL2 y CDRL3, en que: g) CDRH1 comprende la secuencia de aminoácidos de SYGMH (SEQ ID Nº 75); h) CDRH2 comprende la secuencia de aminoácidos de VIWX¹DGSNX²YYADSVX³G (SEQ ID Nº 86), en que: X¹ es Y o F; X² es K o E; y X³ es K o M; i) CDRH3 comprende la secuencia de aminoácidos de NX¹DX² (SEQ ID Nº 87), en que: X¹ es G o V; y X² es H o Y; j) CDRL1 comprende la secuencia de aminoácidos de RASQSVSSNLA (SEQ ID Nº 83); k) CDRL2 comprende la secuencia de aminoácidos de GASTRAT (SEQ ID Nº 84); y l) CDRL3 comprende la secuencia de aminoácidos de QQYNNWPRT (SEQ ID Nº 85).

9. 发明专利

SG11201804265XA ANTIBODIES AND METHODS OF USE THEREOF 未知
公开(公告)号：SG11201804265XA
公开(公告)日：2018-06-28
申请号：SG11201804265X
申请日：2016-12-02
申请人： AGENUS INC , MEMORIAL SLOAN KETTERING CANCER CENTER , LUDWIG INST FOR CANCER RES LTD
发明人： WILSON NICHOLAS S , WAIGHT JEREMY D , RITTER GERD , SCHAER DAVID , HIRSCHHORN-CYMERMAN DANIEL , MERGHOUB TAHA , BREOUS-NYSTROM EKATERINA V , SEIBERT VOLKER , TSUJI TAKEMASA , LEGER OLIVIER , UNDERWOOD DENNIS J , VAN DIJK MARC
IPC分类号： A61K39/395 , A61K47/68 , C07K16/28 , C07K16/30
摘要： The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.

10. 发明专利

CA3046205A1 ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF 未知
公开(公告)号：CA3046205A1
公开(公告)日：2018-06-14
申请号：CA3046205
申请日：2017-12-07
申请人： AGENUS INC , LUDWIG INST FOR CANCER RES LTD , MEMORIAL SLOAN KETTERING CANCER ENTER
发明人： VAN DIJK MARC , MUNDT CORNELIA ANNE , RITTER GERD , SCHAER DAVID , WOLCHOK JEDD DAVID , MERGHOUB TAHA , WILSON NICHOLAS STUART , SAVITSKY DAVID ADAM , FINDEIS MARK ARTHUR , UNDERWOOD DENNIS JOHN , CUILLEROT JEAN-MARIE , PROSCURSHIM IGOR , SHEBANOVA OLGA
IPC分类号： C07K16/28 , A61K39/00
摘要： The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式